Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-11-08
1997-11-11
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 15, 514 17, 530328, 530329, A61K 3808
Patent
active
056864175
ABSTRACT:
A composition useful in treating Multiple Sclerosis and HTLV-1 myelopathy in humans comprises:
i) a peptide having as its active portion, an amino acid sequence of the formula:
REFERENCES:
patent: 4737487 (1988-04-01), Watts et al.
patent: 5162499 (1992-11-01), Trampota et al.
Proc. Natl. Acad. Sci. USA, vol. 83, Dec. 1986, Neurobiology, pp. 9254-9258, Pert, Candace B. et al., "Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity,".
Clinical Neuropharmacology, vol. 9, Suppl. 4, 1986, Raven Press, New York, Sequence in the Aids Virus Envelope Which Blocks Infectivity is Essentially Conserved Across Nine Isolates.".
Brain Research Bulletin, vol. 19, pp. 629-633. Pergamon Journals Ltd., Transported from Blood to Brain by a Saturable System.".
1987 Federation of European Biochemical Societies, vol. 211, No. 1, 17-22, FEB 04365, Jan. 1987, Ruff, Michael R., et al., "CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis.".
Nature, 335, 639-642, Oct. 13, 1988, Brenneman, Douglas E., et al., "Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide.".
Drug Development Research, 15:361-369 (1988), Brenneman, Douglas E., et al., "Peptide T Sequences Prevent Neuronal Cell Death Produced by the Envelope Protein (gp120) of the Human Immunodeficiency Virus.".
Annals New York Academy of Sciences, Komisaruk et al.: Analgesia Produced by VIP, pp. 650-654, "Analgesia Produced by Vasoactive Intestinal Peptide Administered Directly to the Spinal Cord in Rats.".
The Lancet, No. 8656, vol. II for 1989, Boston, Mass. and London, Sat., Jul. 22, 1989, "Improvement in Aids Patients on Peptide T.".
Acta Derm Venereol (Stockh) 1989, Suppl. 146:117-121, Marcusson, Jan A., et al., "Peptide T and Psoriasis.".
Heseltine, Peter et al., Phase I Study of Peptide T in AIDS, Abstract 3105 from IV International Conference on AIDS, Stockholm Sweden, Jun. 1988.
Ruff, Michael R. et al., Pharmacokinetics of Peptide T in Patients with Acquired Immunodeficiency Syndrome (AIDS), Prog. Neuro-Psychopharmacol & Biol. Psychia, 15:791-801 (1991).
MacFadden, D.K. et al., Role of Peptide T in Palliation of HIV-1-Related Painful Peripheral Neuropathy, VIIth International Conference on AIDS, Florence, 1991 W.B. 2173.
Farber, E.M. et al., Peptide T Improves Psoriasis when Infused into Lesions in Nanogram Amounts, J. of American Academy of Dermatology, pp. 658-664 (1991).
Bridge, T.P. et al., Results of Extended Peptide T Administration in AIDS and ARC Patients, Psychopharmacology Bulletin, 27:237-245 (1991).
Bridge, Peter et al., Neuropsychologic Results of Control HIV-1 Trial of Peptide T, VIIth International Conference on AIDS, Abstract Th.B.90, Florence, 1991 W.B. 2173.
Marastoni, M. et al., Synthesis, Metabolic Stability and Chemotactic Activity of Peptide T and its Analogues, Int. J. Peptide Protein Res., 35:81-88 (1990).
Zorn, N.E. et al., Vasoactive Intestinal Peptide and Peptide T Activate Protein Kinase C in Purified Rat Spenocyte Nucleo, The Endoc. Society, Abstract (1989). Abstract 1105, p. 299.
Marcusson et al.; Acta Derm Venereol 1989; Suppl 146:117-121 "Peptide T and Psoriasis".
Bridge et al.; The Lancet 8656, vol. II 1989, Sat. Jul. 22, 1989 "Improvement in AIDS Patients on Peptide T".
Carlen Peter L.
Doob Penelope Reed
MacFadden Douglas K.
Hutzell Paula K.
Prickril Benet
Reed MacFadden, Ltd.
LandOfFree
Peptide T and related peptides in the treatment of HTLV-1 myelop does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide T and related peptides in the treatment of HTLV-1 myelop, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide T and related peptides in the treatment of HTLV-1 myelop will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1229138